Scholar Rock Holding Corporation
SRRK
Peringkat dalam Saham
#3423
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Harga Saham
$41.58
Kapitalisasi Pasar
$5.06B
Perubahan (1 hari)
3.34%
Perubahan (1 tahun)
48.94%
Negara
US
Perdagangan Scholar Rock Holding Corporation (SRRK)
Kategori
Healthcare
Laba untuk Scholar Rock Holding Corporation (SRRK)
Laba pada Jun 2026 TTM: $-408.59M
Menurut laporan keuangan terbaru dari Scholar Rock Holding Corporation, laba saat ini perusahaan adalah $-408.59M. Pada tahun 2023, perusahaan memperoleh laba sebesar $-165.79M, penurunan dibandingkan dengan laba tahun 2022 sebesar $-134.50M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Scholar Rock Holding Corporation dari 2016 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $-408.59M | 65.90% |
| 2024 | $-246.29M | 48.56% |
| 2023 | $-165.79M | 23.26% |
| 2022 | $-134.50M | 2.05% |
| 2021 | $-131.80M | 52.40% |
| 2020 | $-86.48M | 69.57% |
| 2019 | $-51.00M | 3.39% |
| 2018 | $-49.33M | 97.34% |
| 2017 | $-25.00M | 54.22% |
| 2016 | $-16.21M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $5.27B | -1,391.00% |
US
|
|
| $-3.09B | 655.52% |
US
|
|
| $-4.02B | 882.94% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -577.41% |
NL
|
